Drug Trial Radar · NCT05757713
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Jul 25, 2023
Primary completion
Aug 28, 2026
Study completion Aug 28, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.
Conditions
- Diabetes Mellitus, Type 1
Interventions
teplizumabBiological
CD3-directed humanized monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)Time frame: Through 104 Weeks
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
UCSF Medical Center Site Number : 107
San Francisco, California
Barbara Davis Center for Diabetes Site Number : 102
Aurora, Colorado
Yale University School of Medicine Site Number : 101
New Haven, Connecticut
Centricity Research Site Number : 104
Columbus, Georgia
Indianapolis University Health Riley Hospital for Children Site Number : 110
Indianapolis, Indiana
UBMD Pediactrics Site Number : 105
Buffalo, New York
Children's Hospital of Philadelphia Site Number : 108
Philadelphia, Pennsylvania
Sanford Diabetes and Thyroid Clinic Site Number : 106
Sioux Falls, South Dakota
Vanderbilt Univerity Medical Center Site Number : 109
Nashville, Tennessee
MulitCare Institute for Research & Innovation Site Number : 103
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.